<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99171">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950858</url>
  </required_header>
  <id_info>
    <org_study_id>91/12*1</org_study_id>
    <nct_id>NCT01950858</nct_id>
  </id_info>
  <brief_title>Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee</brief_title>
  <official_title>Safety and Efficacy of Hyper Baric Oxygen Therapy (HBOT) in Patients Presenting With Spontaneous Osteonecrosis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      safety and efficacy of Hyper Baric Oxygen (HBO) in patients presenting with spontaneous
      osteonecrosis of the knee
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain Reduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>end of HBOT</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of Participants with Adverse Events during HBOT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction In AVN size by  MRI</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Spontaneous Osteonecrosis of the Knee</condition>
  <arm_group>
    <arm_group_label>Biological</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 weeks of  HBO treatment as well as  non weight bearing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non weight bearing</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Weight reduction</intervention_name>
    <arm_group_label>Biological</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age40-85 years

          -  Diagnosis of Spontaneous osteonecrosis of the knee (SONK)in last month, Stage 1 or 2
             by MRI.

        Exclusion Criteria:

          -  Hyperbaric treatment (HBOT) in the last 2 years.

          -  Any contraindication for HBOT

          -  Pregnancy.

          -  Inability to sign inform consent

          -  Any contraindication for MRI
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Months</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shai Efrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiftah Beer, MD</last_name>
    <phone>972-8-9779432</phone>
    <email>yiftah.beer@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiftah Beer, MD</last_name>
      <phone>972-8-9779432</phone>
      <email>yiftah.beer@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 19, 2013</lastchanged_date>
  <firstreceived_date>August 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assaf-Harofeh Medical Center</investigator_affiliation>
    <investigator_full_name>Assaf Harofeh MC</investigator_full_name>
    <investigator_title>Yiftah Beer</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
